European Myeloma Network Sequential Phase I / Phase II Trial on RIC Allogeneic Transplantation: an Optimized Program for High Risk Relapsed Patients
Phase of Trial: Phase I/II
Latest Information Update: 10 Jul 2017
At a glance
- Drugs Bortezomib (Primary) ; Lenalidomide (Primary)
- Indications Graft-versus-host disease; Haematological malignancies; Multiple myeloma
- Focus Adverse reactions
- Acronyms EMN-alloRIC
- 05 Jul 2017 Status changed from recruiting to completed.
- 29 Nov 2016 Planned End Date changed from 1 May 2016 to 1 Jun 2017.
- 29 Nov 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Jun 2017.